VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that members of the management team will discuss VBI-2601, the Company’s vaccine immunotherapeutic candidate in development for a functional cure for hepatitis B (HBV) infection, in a fireside chat at the H.C. Wainwright Hepatitis B Virus (HBV) Mini-Conference on Tuesday, October 20, 2020, at 2:00 PM ET.
- Event: H.C. Wainwright HBV Mini-Conference – Virtual
- Presenters: Jeff Baxter, VBI’s President and CEO, and David E. Anderson, Ph.D., VBI’s Chief Scientific Officer
- Date: Tuesday, October 20, 2020
- Time: 2:00 – 2:30 PM ET
- Webcast: https://journey.ct.events/view/0a5ed8a2-b6b8-43d8-b016-0f1b4c5e7e05
A recording of the webcast will be available on the “Events/Presentations” page in the “Investors” section of VBI’s website.
About Hepatitis B
Hepatitis B is one of the world’s most significant infectious disease threats with more than 290 million people infected globally. HBV infection is the leading cause of liver disease and, with no available cure, many patients go on to develop liver cancer or cirrhosis. An estimated 780,000 people die each year from complications of chronic HBV such as liver decompensation and hepatocellular carcinoma.